Report Overview

The South Korea Hunter syndrome market size stood at around USD 18.65 million in 2019 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx % during the forecast period.

Hunter syndrome, also known as mucopolysaccharidosis II or MPS II, is a type of rare disease caused by a lysosomal enzyme or iduronate-2-sulfatase enzyme deficiency. Hunter syndrome, a type of congenital metabolic disorder, is a rare disease that occurs in 1 in 100,000 to 150,000 people. Patients who do not receive timely treatment show unpredictable symptoms such as skeletal abnormalities and intellectual decline, and the prognosis is so poor that they die prematurely around the age of 15. There were only about 70- 80 patients suffering from Hunter syndrome in South Korea as of 2019.



Market Drivers

The market growth is ascribed to the introduction of new therapies, and many drugs that are in pipelines. Increasing R&D activities by key players for the development of such novel therapies will drive the market growth in the near future.In addition, growing awareness about Hunter syndrome and the availability of therapeutic options may propel the revenue growth of the market.